1 June 2026

MedPal AI plc

("MedPal AI", "MedPal" or the "Company")

Pharmacy Operational Update

Record Monthly Dispensing Volume - Best Month Since Launch

Over 250,000 Prescription Items Dispensed Since Launch

MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-powered, integrated digital health and pharmacy company, is pleased to provide an operational update on the continued strong growth in dispensing volumes at its wholly owned pharmacy operations.

•   Record month: over 42,250 prescription items dispensed in May 2026 - the Company's best-performing month since pharmacy operations commenced, surpassing the previous record of 41,000 items, reflecting underlying momentum in patient demand.

•   Major cumulative milestone: the Company has now dispensed over 250,000 prescription items in total since launch, underscoring the sustained, accelerating adoption of its NHS and private pharmacy services and the Company's dispensing platform retains substantial headroom for further growth.

•   Strong margins: as reported in the Company's interim results for the six months ended 28 February 2026, pharmacy gross margin strengthened to over 34% as dispensing volumes scaled, reflecting the operational leverage of the Company's automated dispensing model.

•   Annualised run rate: based on the May 2026 dispensing volume the Company's pharmacy operations are now trading at an annualised turnover run rate in excess of £5 million.

Chief Executive Officer's commentary

Jason Drummond, Founder and Chief Executive Officer of MedPal AI, commented:

"May was our best month yet, with over 42,250 items dispensed, and we have now passed a quarter of a million prescriptions since we began. To reach this scale in such a short period is a powerful validation of our automated, technology-led model - which, as our interim results showed, is delivering pharmacy gross margins of over 34% as we grow. We have built this momentum from a standing start, and with significant capacity still available across our dispensing operations, the Board sees a clear runway for continued, profitable growth."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Enquiries:

About MedPal AI

MedPal AI is a UK-based digital health company building the MedPal Health OS - a vertically integrated, closed-loop platform spanning AI wellness, clinical services, and automated pharmacy fulfilment. Its core app aggregates data from over 100 wearable devices and health apps (including Apple Health, Fitbit, Garmin, and Whoop) into a unified health profile, offering personalised, non-clinical lifestyle guidance through its AI wellness coach and acting as the consumer front door to the Company's clinical and pharmacy services.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages BD Rowa VMAX robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms. The Company's LEI is 984500EDP8B0A14CBA61.

Forward Looking Statements

This announcement contains forward-looking statements, which are based on the Company's current expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. Forward-looking statements are often identified by words such as "believes", "expects", "intends", "may", "will", "should", "could", "plans", "targets", "aims" or similar expressions. Such statements are subject to risks, assumptions and uncertainties and actual results, performance or events may differ materially from those expressed or implied by them. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law, the AIM Rules for Companies, the UK Market Abuse Regulation or other applicable regulation.